Chimeric antigen receptor (CAR) T cell therapies have transformed outcomes for many
patients with hematological malignancies. However, some patients do not respond to CAR T …

Neuroblastoma is the most common extracranial solid tumor found in childhood and is
responsible for 15% of deaths among children with cancer. Although multimodal therapies …

Chimeric antigen receptor (CAR) T cell immunotherapy in solid cancer is severely limited by
the absence of ideal targets. In this issue of Cancer Cell, Bergaggio et al. find that anaplastic …

Despite low incidence, neuroblastoma, an immunologically cold tumor, is the most common
extracranial solid neoplasm in pediatrics. In relapsed/refractory cases, the benefits of …

Abstract Histone Deacetylase 6 (HDAC6) is an essential regulator of histone acetylation
processes, exerting influence on a multitude of cellular functions such as cell motility …

Lorlatinib is a pharmaceutical ALK kinase inhibitor used to treat ALK driven non-small cell
lung cancers. This paper analyses the intersection of past published data on the …

The recently published landmark paper by Bergaggio et al. from Roberto Chiarle's group in
Cancer Cell 1 investigates an elegant double-hit strategy to improve anti-cancer …

The rise in biological therapies has revolutionized oncology, with immunotherapy leading
the charge through breakthroughs such as CAR-T cell therapy for melanoma and B-ALL …

Cancer immunotherapies have produced remarkable results in B-cell malignancies;
however, optimal cell surface targets for many solid cancers remain elusive. Here, we …

Simple Summary Neuroblastoma (NBL) is the most common extracranial cancer in children.
High-risk NBL is characterized by bone marrow metastasis and MYCN oncogene …